Automatic injection device
First Claim
1. A method for treating a disorder in which TNFα
- activity is detrimental in a subject, the method comprising;
using adalimumab to treat the disorder by subcutaneous injection, the adalimumab contained in an automatic injection device with a housing having an open first end and a second end;
biasing a syringe actuation component in the housing with a first biasing mechanism for first moving a syringe disposed in the housing towards the first end of the housing such that a hollow needle in fluid communication with a syringe barrel holding the adalimumab projects from the first end and for subsequently applying pressure to a bung sealing the syringe barrel to force the adalimumab through the hollow needle;
wherein the syringe actuation component comprises a pressurizer, at a first end of the syringe actuation component, for selectively applying pressure to the bung, a rod comprising a compressible portion projecting from the rod along at least a portion of a length of the rod, the compressible portion having a first expanded position prior to entering the barrel portion of the syringe and a second compressed position for initiating movement of the bung and a flange between a second end of the syringe actuation component and the compressible portion; and
wherein the first biasing mechanism is disposed between the flange of the syringe actuation component and the second end of the housing.
4 Assignments
0 Petitions
Accused Products
Abstract
A method for treating a disorder using an automatic injection device is disclosed. The device includes a syringe movably disposed in a housing and including a barrel portion, a needle and a bung for sealing the barrel portion. The device includes a syringe actuation component for moving the syringe towards a first open end of the housing such that the needle projects from the first end, and for subsequently applying pressure to the bung. The syringe actuation component includes a pressurizer, a rod comprising a compressible portion projecting therefrom, and a flange between a second end of the rod and the compressible portion. The device also includes a biasing mechanism for biasing the syringe actuation component towards the first open end of the housing, the biasing mechanism disposed about the second end of the rod between the flange and a second end of the housing.
507 Citations
28 Claims
-
1. A method for treating a disorder in which TNFα
- activity is detrimental in a subject, the method comprising;
using adalimumab to treat the disorder by subcutaneous injection, the adalimumab contained in an automatic injection device with a housing having an open first end and a second end; biasing a syringe actuation component in the housing with a first biasing mechanism for first moving a syringe disposed in the housing towards the first end of the housing such that a hollow needle in fluid communication with a syringe barrel holding the adalimumab projects from the first end and for subsequently applying pressure to a bung sealing the syringe barrel to force the adalimumab through the hollow needle; wherein the syringe actuation component comprises a pressurizer, at a first end of the syringe actuation component, for selectively applying pressure to the bung, a rod comprising a compressible portion projecting from the rod along at least a portion of a length of the rod, the compressible portion having a first expanded position prior to entering the barrel portion of the syringe and a second compressed position for initiating movement of the bung and a flange between a second end of the syringe actuation component and the compressible portion; and wherein the first biasing mechanism is disposed between the flange of the syringe actuation component and the second end of the housing. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- activity is detrimental in a subject, the method comprising;
-
16. A method for treating a disorder in which TNFα
- activity is detrimental in a subject, the method comprising;
using adalimumab to treat the disorder by subcutaneous injection, the adalimumab contained in an automatic injection device with a housing having an open first end and a second end; biasing a plunger in the housing with a biasing mechanism towards the open first end of the housing; wherein the plunger comprises a rod configured to be connected or adjacent at a first end to a bung of a syringe, a compressible portion projecting from the rod along at least a portion of a length of the rod, the compressible portion having a first expanded inactivated position and a second compressed activated position for initiating movement of the bung, and a flange between a second end of the rod and the compressible portion; and wherein the biasing mechanism is disposed about the second end of the rod between the flange and the second end of the housing. - View Dependent Claims (17, 18, 19, 20)
- activity is detrimental in a subject, the method comprising;
-
21. A method for treating a disorder in which TNFα
- activity is detrimental in a subject, the method comprising;
using adalimumab to treat the disorder by subcutaneous injection, the adalimumab contained in an automatic injection device with a housing having an open first end, a second end, a window disposed in a side wall for viewing the interior of the housing and indicator that aligns with the window when the adalimumab has been injected into the user; biasing a syringe actuation component in the housing with a first biasing mechanism for first moving a syringe movably disposed in the housing towards the open first end of the housing such that a hollow needle in fluid communication with the a barrel portion of the syringe holding the adalimumab projects from the open first end and for subsequently applying pressure to a bung sealing the barrel portion and selectively applying pressure to the adalimumab to force the adalimumab through the hollow needle; wherein the syringe actuation component comprises a rod having an upper solid portion having a first end, a lower solid portion having a second end operable to move the bung and to transmit an expulsion force thereto, and a projecting portion projecting from the rod along at least a portion of a length of the rod, the projecting portion comprising two or more flexible elbows on either side of a central void provided between the upper and lower solid portions and aligned along a central axis of the rod, the projecting portion having a first expanded position prior to entering the barrel portion of the syringe in which the flexible elbows project radially outwardly to form the central void, and the projecting portion having a second compressed position for applying the second end of the lower solid portion to the bung in which the flexible elbows are compressed radially inwardly toward the central void, and a flange disposed between the first end of the upper solid portion of the rod and the projecting portion of the rod; wherein the first biasing mechanism is disposed between the flange of the syringe actuation component and the second end of the housing; wherein the housing comprises a second biasing mechanism for holding the syringe retracted in the housing until the first biasing mechanism is released; and removing a first removable cap that covers the open first end of the housing or the second end of the housing. - View Dependent Claims (22, 23, 24, 25, 26, 27, 28)
- activity is detrimental in a subject, the method comprising;
Specification